|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000253313 |
Summary for C1orf210 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000253313 | Gene symbol | C1orf210 |
| Gene name | chromosome 1 open reading frame 210 | |
| HGNC | 28755 | |
| Entrez ID | 149466 | |
| Gene type | protein_coding | |
| Synonyms | C1orf210|MGC52423|TEMP | |
| UniProtAcc | Q8IVY1 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for C1orf210 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| C1orf210 | 4.83e+02 | 1.31e+00 | 4.03e-01 | 3.26e+00 | 1.12e-03 | 3.64e-03 | BLCA |
| C1orf210 | 1.09e+03 | -1.03e+00 | 3.76e-01 | -2.73e+00 | 6.38e-03 | 1.35e-02 | KICH |
| C1orf210 | 7.52e+02 | 1.46e+00 | 4.42e-01 | 3.32e+00 | 9.11e-04 | 3.13e-03 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| C1orf210 | 9.46e+02 | -1.18e+00 | 2.52e-01 | -4.67e+00 | 2.99e-06 | 2.27e-05 | READ |
Top |
Sex-biased somatic mutation for C1orf210 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for C1orf210 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg23800435 | chr1:43285705 | CGI:chr1:43272813-43273158 | promoter | 3.61e-01 | 2.54e-01 | 2.79e+00 | 5.26e-03 | 2.08e-02 | 1.07e-01 |
| BRCA | cg01413566 | chr1:43284969 | CGI:chr1:43272813-43273158 | promoter,gene body | 4.75e-01 | 3.71e-01 | 3.06e+00 | 2.22e-03 | 1.43e-02 | 1.04e-01 |
| BRCA | cg12752420 | chr1:43285692 | CGI:chr1:43272813-43273158 | promoter | 4.62e-01 | 3.25e-01 | 2.86e+00 | 4.18e-03 | 1.89e-02 | 1.37e-01 |
| BRCA | cg00500789 | chr1:43285699 | CGI:chr1:43272813-43273158 | promoter | 4.24e-01 | 3.11e-01 | 2.52e+00 | 1.16e-02 | 2.82e-02 | 1.13e-01 |
| BRCA | cg09988116 | chr1:43285022 | CGI:chr1:43272813-43273158 | promoter,gene body | 5.56e-01 | 4.31e-01 | 2.75e+00 | 5.91e-03 | 2.18e-02 | 1.25e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg01413566 | chr1:43284969 | CGI:chr1:43272813-43273158 | promoter,gene body | 5.45e-01 | 4.25e-01 | 5.58e+00 | 2.48e-08 | 1.53e-07 | 1.20e-01 |
| KIRC | cg24464789 | chr1:43285826 | CGI:chr1:43272813-43273158 | promoter | 5.28e-01 | 4.04e-01 | 4.43e+00 | 9.21e-06 | 2.52e-05 | 1.24e-01 |
| LUSC | cg23800435 | chr1:43285705 | CGI:chr1:43272813-43273158 | promoter | 4.15e-01 | 5.47e-01 | -3.49e+00 | 4.83e-04 | 1.62e-03 | -1.31e-01 |
| LUSC | cg04289036 | chr1:43285599 | CGI:chr1:43272813-43273158 | UTR,promoter,exon,gene body | 4.42e-01 | 5.73e-01 | -3.84e+00 | 1.21e-04 | 7.60e-04 | -1.30e-01 |
| LUSC | cg12752420 | chr1:43285692 | CGI:chr1:43272813-43273158 | promoter | 5.20e-01 | 6.91e-01 | -3.40e+00 | 6.72e-04 | 2.00e-03 | -1.70e-01 |
| LUSC | cg00500789 | chr1:43285699 | CGI:chr1:43272813-43273158 | promoter | 4.78e-01 | 6.46e-01 | -3.67e+00 | 2.43e-04 | 1.08e-03 | -1.67e-01 |
| LUSC | cg24464789 | chr1:43285826 | CGI:chr1:43272813-43273158 | promoter | 4.85e-01 | 7.27e-01 | -3.95e+00 | 7.91e-05 | 6.37e-04 | -2.42e-01 |
| LUSC | cg02990330 | chr1:43285833 | CGI:chr1:43272813-43273158 | promoter | 4.79e-01 | 6.10e-01 | -3.53e+00 | 4.11e-04 | 1.47e-03 | -1.30e-01 |
| LUSC | cg14036856 | chr1:43285892 | CGI:chr1:43272813-43273158 | promoter | 4.03e-01 | 5.74e-01 | -3.79e+00 | 1.52e-04 | 8.45e-04 | -1.70e-01 |
| COAD | cg24464789 | chr1:43285826 | CGI:chr1:43272813-43273158 | promoter | 3.40e-01 | 4.41e-01 | -2.55e+00 | 1.07e-02 | 1.51e-02 | -1.01e-01 |
| CHOL | cg01413566 | chr1:43284969 | CGI:chr1:43272813-43273158 | promoter,gene body | 4.50e-01 | 7.62e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -3.12e-01 |
| CHOL | cg09988116 | chr1:43285022 | CGI:chr1:43272813-43273158 | promoter,gene body | 5.15e-01 | 8.71e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -3.56e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg23800435 | chr1:43285705 | CGI:chr1:43272813-43273158 | promoter | 3.61e-01 | 4.82e-01 | -8.16e+00 | 3.36e-16 | 1.34e-15 | -1.21e-01 |
| BRCA | cg01413566 | chr1:43284969 | CGI:chr1:43272813-43273158 | promoter,gene body | 4.75e-01 | 5.80e-01 | -9.01e+00 | 1.99e-19 | 1.02e-18 | -1.05e-01 |
| BRCA | cg12752420 | chr1:43285692 | CGI:chr1:43272813-43273158 | promoter | 4.62e-01 | 6.34e-01 | -8.63e+00 | 6.22e-18 | 2.84e-17 | -1.72e-01 |
| BRCA | cg00500789 | chr1:43285699 | CGI:chr1:43272813-43273158 | promoter | 4.24e-01 | 5.80e-01 | -8.41e+00 | 3.96e-17 | 1.70e-16 | -1.56e-01 |
| BRCA | cg09988116 | chr1:43285022 | CGI:chr1:43272813-43273158 | promoter,gene body | 5.56e-01 | 6.85e-01 | -7.65e+00 | 2.08e-14 | 7.26e-14 | -1.29e-01 |
| BRCA | cg24464789 | chr1:43285826 | CGI:chr1:43272813-43273158 | promoter | 4.33e-01 | 6.80e-01 | -1.04e+01 | 2.45e-25 | 2.15e-24 | -2.47e-01 |
| BRCA | cg02990330 | chr1:43285833 | CGI:chr1:43272813-43273158 | promoter | 4.51e-01 | 6.16e-01 | -9.37e+00 | 7.59e-21 | 4.41e-20 | -1.65e-01 |
| BRCA | cg14036856 | chr1:43285892 | CGI:chr1:43272813-43273158 | promoter | 3.56e-01 | 4.93e-01 | -8.71e+00 | 2.99e-18 | 1.40e-17 | -1.37e-01 |
| HNSC | cg00500789 | chr1:43285699 | CGI:chr1:43272813-43273158 | promoter | 5.12e-01 | 3.95e-01 | 1.98e+00 | 4.78e-02 | 4.82e-02 | 1.18e-01 |
| HNSC | cg09988116 | chr1:43285022 | CGI:chr1:43272813-43273158 | promoter,gene body | 7.38e-01 | 5.43e-01 | 2.71e+00 | 6.64e-03 | 1.52e-02 | 1.96e-01 |
| HNSC | cg14036856 | chr1:43285892 | CGI:chr1:43272813-43273158 | promoter | 4.26e-01 | 3.18e-01 | 2.10e+00 | 3.54e-02 | 3.95e-02 | 1.08e-01 |
| HNSC | cg19086488 | chr1:43286514 | CGI:chr1:43272813-43273158 | promoter | 7.98e-01 | 9.04e-01 | -3.16e+00 | 1.60e-03 | 9.36e-03 | -1.05e-01 |
| BLCA | cg23800435 | chr1:43285705 | CGI:chr1:43272813-43273158 | promoter | 3.54e-01 | 5.37e-01 | -3.19e+00 | 1.44e-03 | 5.74e-03 | -1.83e-01 |
| BLCA | cg04289036 | chr1:43285599 | CGI:chr1:43272813-43273158 | UTR,promoter,exon,gene body | 3.74e-01 | 5.36e-01 | -3.09e+00 | 2.01e-03 | 6.81e-03 | -1.62e-01 |
Top |
Exon skipping events with PSI in TCGA for C1orf210 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for C1orf210 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for C1orf210 |
| TFs related to C1orf210. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHOL | SNAI1 | C1orf210 | 4.00e+00 | 9.83e-01 | 2.87e+00 | 5.14e-03 | Male-biased |
| CHOL | ZNF200 | C1orf210 | 4.28e+00 | 9.84e-01 | 3.27e+00 | 8.48e-03 | Male-biased |
| GBM | ZNF235 | C1orf210 | 3.04e+00 | 1.33e-03 | 4.87e+00 | 9.95e-01 | Female-biased |
| GBM | ZNF287 | C1orf210 | 3.00e+00 | 1.85e-03 | 4.71e+00 | 9.94e-01 | Female-biased |
| GBM | ZNF487 | C1orf210 | 3.07e+00 | 3.16e-03 | 4.58e+00 | 9.92e-01 | Female-biased |
| C1orf210 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for C1orf210 |
| RBPs related to ES in C1orf210. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| C1orf210 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000253313 | ZNF687-AS1,hsa-mir-665,C1orf210 | Male-specific ceRNA | TCGA-BLCA |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12409819 | chr1:41548263:T:C | - | 0.133471441275208 | 0.00764603714884252 | COAD | Female-baised eQTL |
| rs78710926 | chr1:41549529:G:T | - | 0.133471441275208 | 0.00764603714884252 | COAD | Female-baised eQTL |
| rs80115073 | chr1:41550141:C:A | - | 0.133471441275208 | 0.00764603714884252 | COAD | Female-baised eQTL |
| rs72951401 | chr1:41556685:T:C | - | 0.133471441275208 | 0.00764603714884252 | COAD | Female-baised eQTL |
| rs57379984 | chr1:41560408:G:A | - | 0.133471441275208 | 0.00764603714884252 | COAD | Female-baised eQTL |
| rs56256181 | chr1:41562708:A:G | - | 0.133471441275208 | 0.00764603714884252 | COAD | Female-baised eQTL |
| rs2181276 | chr1:41563463:G:A | - | 0.128898453058873 | 0.0113255576801295 | COAD | Female-baised eQTL |
| rs66604456 | chr1:41539512:G:A | - | 0.131540135345632 | 0.012728679357504 | COAD | Female-baised eQTL |
| rs59330427 | chr1:41534896:G:C | - | 0.131218265808127 | 0.0133791348215805 | COAD | Female-baised eQTL |
| rs1258012 | chr1:46606472:A:G | - | 0.0752939937368727 | 0.0142977108731903 | COAD | Female-baised eQTL |
| rs11211323 | chr1:46605736:G:C | - | -0.0743779918799342 | 0.0154552477966695 | COAD | Female-baised eQTL |
| rs11264095 | chr1:37734325:G:C | - | 0.0926627311280825 | 0.0171031120205822 | COAD | Female-baised eQTL |
| rs10890406 | chr1:46603005:C:T | - | -0.0738858801143807 | 0.0171714362355717 | COAD | Female-baised eQTL |
| rs2297850 | chr1:46576940:C:T | - | 0.0697729093182361 | 0.0174423615393848 | COAD | Female-baised eQTL |
| rs942083 | chr1:46611309:G:C | - | 0.0726158202562676 | 0.0179759397481444 | COAD | Female-baised eQTL |
| rs10890408 | chr1:46610826:A:G | - | -0.0728995627471132 | 0.019106988503438 | COAD | Female-baised eQTL |
| rs11211324 | chr1:46610916:C:A | - | -0.0710681853139889 | 0.0194956150661361 | COAD | Female-baised eQTL |
| rs11211325 | chr1:46610927:A:C | - | -0.0710681853139889 | 0.0194956150661361 | COAD | Female-baised eQTL |
| rs11211326 | chr1:46612637:C:G | - | -0.0716955749497166 | 0.0225433100432593 | COAD | Female-baised eQTL |
| rs11211327 | chr1:46612646:T:C | - | -0.0716955749497166 | 0.0225433100432593 | COAD | Female-baised eQTL |
| rs4660357 | chr1:46601601:C:T | - | -0.0721162459796972 | 0.0230248039215923 | COAD | Female-baised eQTL |
| rs6687832 | chr1:46602151:T:C | - | -0.0721162459796972 | 0.0230248039215923 | COAD | Female-baised eQTL |
| rs36058295 | chr1:46602823:A:G | - | -0.0713547538242908 | 0.0249066500598968 | COAD | Female-baised eQTL |
| rs956527 | chr1:46590320:T:C | - | 0.0670500814646912 | 0.0271579882031085 | COAD | Female-baised eQTL |
| rs11211319 | chr1:46600711:T:C | - | -0.0712971869236416 | 0.0271925871653082 | COAD | Female-baised eQTL |
| rs11211320 | chr1:46601073:T:C | - | -0.0712971869236416 | 0.0271925871653082 | COAD | Female-baised eQTL |
| rs12136479 | chr1:46602678:A:G | - | -0.0713873731664774 | 0.0276828238928945 | COAD | Female-baised eQTL |
| rs10890407 | chr1:46604058:A:G | - | -0.0706302421327305 | 0.0298516944363036 | COAD | Female-baised eQTL |
| rs4660947 | chr1:46612965:T:C | - | -0.0676554784578197 | 0.0371314663461941 | COAD | Female-baised eQTL |
| rs116516140 | chr1:40012377:A:T | - | 0.114353426763399 | 0.0372375841175174 | COAD | Female-baised eQTL |
| rs12022855 | chr1:46602912:C:T | - | -0.0697417994173807 | 0.0407413316081878 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2810581 | chr1:41471224:T:C | - | -0.147507452899043 | 0.0233414988916025 | KIRP | Male-baised eQTL |
| rs523755 | chr1:43048650:G:A | - | 0.0809611918657329 | 0.0457967164522068 | KIRP | Male-baised eQTL |
| rs16828535 | chr1:41676802:G:A | - | 0.131880060725213 | 0.00667778050616806 | LUAD | Male-baised eQTL |
| rs12409546 | chr1:36016250:C:T | - | 0.14265326987306 | 0.0404039047823042 | LUAD | Male-baised eQTL |
| rs55657908 | chr1:43261717:G:A | - | 0.0584278230896553 | 0.0292609269742866 | COAD | Male-baised eQTL |
| rs2764417 | chr1:43242901:G:T | - | 0.0585039914596941 | 0.0305045542640212 | COAD | Male-baised eQTL |
| rs35509903 | chr1:43247986:G:A | - | 0.0575905563018201 | 0.0330610747666123 | COAD | Male-baised eQTL |
| rs2484713 | chr1:43258759:G:A | - | 0.0571699034342052 | 0.0343576152418847 | COAD | Male-baised eQTL |
| rs6657897 | chr1:43247770:C:T | - | 0.0569432734072431 | 0.0357606237216231 | COAD | Male-baised eQTL |
| rs9429132 | chr1:43265670:A:G | - | 0.0561577977998001 | 0.0378080275596838 | COAD | Male-baised eQTL |
| rs524158 | chr1:47467422:G:T | - | -0.0495411879209577 | 0.0404900478407521 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000253313 |
| CpG Site: cg19234495 | |
| Position to Gene: gene,exon,CDS | |
| Male Effect: - | |
| Female Effect: -0.413331571101973 | |
 | Gene ID: ENSG00000253313 |
| CpG Site: cg09988116 | |
| Position to Gene: gene,promoter | |
| Male Effect: - | |
| Female Effect: -0.447453847007151 | |
 | Gene ID: ENSG00000253313 |
| CpG Site: cg02990330 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.447453847007151 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg19234495 | chr1:43282992 | gene,exon,CDS | -0.413331571101973 | 4.61618165179225e-09 | -0.6761687131979955 | 5.8754765921287225e-12 | PAAD |
| cg09988116 | chr1:43285022 | gene,promoter | -0.447453847007151 | 3.61704256955315e-23 | -0.6059402422034701 | 5.99796020665408e-27 | LUAD |
| cg02990330 | chr1:43285833 | promoter | -0.447453847007151 | 3.61704256955315e-23 | -0.6059402422034701 | 5.99796020665408e-27 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of C1orf210 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
